Table 2.
Indicators | Austria | Belgium | Croatia | Denmark | France | Germany | Italy | Netherlands | Portugal | Romania | Spain | Sweden | Switzerland | UK | Canada | US | Australia | Japan |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Estimated number of Latin American immigrants | 7552 | 38,133 | ND | ND | 208,395 | 58,000 | 440,000 | 35,211 | 83,000 | ND | 2,090,695 | 58,196 | 60,000–90,000 | 400,000 | 100,000 | 22,000,000 | 116,430 | 371,700 |
Estimated number of T. cruzi cases | 140–180 | 1982 | ND | ND | 2116 | 935 | 5,520–7,081 | 480 | 850 | ND | 47,738–67,423 | 1,118 | 3,000 | 14,000 | 1,789 | 300,167 | 1,928 | 3,592 |
Number of laboratory confirmed cases | 2 | 19 | 1 | 1 | 111 | 2 | 114 | 7 | 8 | 1 | 3,617 | 1 | 256 | 28 | 1 | 799 | 1 | 46 |
Estimated number of pregnant women with T. cruzi infection | ND | 16 | ND | ND | ND | ND | 30 | 18 | 50 | ND | 914–1,656 | ND | 30 | 50 | ND | ND | ND | ND |
Estimated number of cases of congenital transmission |
ND | 1 | ND | ND | 19 | ND | 2 | 2 | 2 | ND | 41–121 | 1 | 5 | 5 | ND | ND | ND | ND |
Number of patients treated + | 2 | 3 | ND | ND | 28 | ND | 22 | ND | ND | ND | 195 | 1 | 99 | 0 | ND | ND | ND | ND |
Serological screening of blood donors | Yes | No | No | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | Yes | No | Yes | No | No |
Presence of a systematic detection system for congenital infection | No | No | No | No | No | No | Yesc | No | No | No | Yesc | No | Yesc | Nob | No | No | No | No |
Presence of a systematic detection system for organ, tissue, and cell donors of T. cruzi | No | No | No | No | Yes | No | Yes | Yesa | No | No | Yes | NO | No | Yes | No | No | No | No |
* Data sourced from [29, 44–46, 49]
+ Treated with benznidazole or nifurtimox
ND Not determined
aOnly known Chagas disease patients are excluded from donating blood or organs, tissues, and cells for transplantation
bAdvocacy is carried out for screening of at-risk mothers
cOnly in some regions or communities